Clinical trials: Stage IB Melanoma
Metastatic Melanoma
Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
The goal of this study is to determine a safe dose of GR-MD-02 used in combination with the FDA-approved dose of ipilimumab (3 mg/kg) in patients who have advanced melanoma. GR-MD-02 is a galectin.
- Trial name
- NCT02117362
- Testing
- 1 mg/kg GR-MD-02, 2 mg/kg GR-MD-02, 4 mg/kg GR-MD-02
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Providence Health & Services
Melanoma
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
This study will evaluate the safety, pharmacokinetics, and activity of belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus nivolumab in patients with NRAS-mutant advanced melanoma who…
- Trial name
- NCT04835805
- Testing
- Belvarafenib, Cobimetinib, Nivolumab
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 65 people
- Sponsor
- Genentech, Inc.
Melanoma
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
This study will evaluate the efficacy, safety, and pharmacokinetics of treatment combinations in cancer immunotherapy (CIT)-naive participants with resectable Stage III melanoma (Cohort 1) and in participants with Stage IV…
- Trial name
- NCT05116202
- Testing
- Nivolumab, Ipilimumab, RO7247669 2100 mg
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 110 people
- Sponsor
- Hoffmann-La Roche
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Melanoma
Phase I trial to study the effectiveness of vaccine therapy in treating patients with melanoma that cannot be treated with surgery. Vaccines may make the body build an immune response that may kill tumor cells.
- Trial name
- NCT00003556
- Testing
- ALVAC-hB7.1, canarypox-hIL-12 melanoma vaccine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8
Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial
This clinical trial compares the effect of a narrow surgical excision (removal) to a wide excision for the treatment of adults with invasive cutaneous melanoma.
- Trial name
- NCT06673095
- Testing
- Biospecimen Collection, Excision, Survey Administration
- Where
- 5 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- OHSU Knight Cancer Institute
Melanoma, Stage I, Melanoma, Stage II
Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG
In this study the investigators try to identify the sentinel lymph node in patients with stage Ib-III melanoma in a non-invasive manner without the use of a radioactive tracer by using the new MSOT technology.
- Conditions
- Melanoma, Stage I, Melanoma, Stage II, Melanoma Stage III
- Trial name
- MelanooMSOT (NCT05467137)
- Testing
- MSOT
- Volunteers
- 10 people
- Sponsor
- University Medical Center Groningen
Malignant Melanoma
A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
This open-label, dose-escalation study of vemurafenib in combination with cobimetinib will evaluate the safety, tolerability and pharmacokinetics in participants with BRAFV600 mutation-positive metastatic melanoma.
- Trial name
- NCT01271803
- Testing
- Cobimetinib, vemurafenib
- Where
- 10 sites in United States, Australia
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Melanoma (Skin), Intraocular Melanoma
Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation
The purpose of this study is to evaluate the safety and immunogenicity of a DNA vaccine encoding a melanosomal antigen in melanoma patients at risk for disease progression or recurrence.
- Trial name
- NCT00471133
- Testing
- Xenogeneic Tyrosinase DNA Vaccine, TriGrid Delivery System for Intramuscular Electroporation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ichor Medical Systems Incorporated
Melanoma, In-Transit Metastasis
Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion
To evaluate safety and the effect of isolated limb perfusion together with nivolumab as a way to increase efficacy and give further insights in early immunological mechanisms.
- Trial name
- NivoILP (NCT03685890)
- Testing
- Nivolumab, Isolated limb perfusion (ILP)
- Where
- 4 sites in Netherlands, Sweden
- Volunteers
- 74 people
- Sponsor
- Vastra Gotaland Region
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Malignant Melanoma
Tinostamustine and Nivolumab in Advanced Melanoma
This trial is a first-in-human drug combination with the first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule Tinostamustine (EDO-S101) and the anti-PD-1 monoclonal antibody Nivolumab in patients with…
- Trial name
- ENIgMA (NCT03903458)
- Testing
- Tinostamustine
- Where
- 2 sites in Switzerland
- Volunteers
- 21 people
- Sponsor
- Markus Joerger
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
This clinical trial will evaluate the safety and feasibility of a humanized OX40 agonist, MEDI0562, in the pre-operative setting for patients with head and neck squamous cell carcinoma or melanoma.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Cell Cancer, Squamous
- Trial name
- NCT03336606
- Testing
- MEDI0562
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Providence Health & Services
Melanoma Stage IV, Unresectable Melanoma
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC
A Phase Ib trial to evaluate the safety and efficacy of Fecal Microbial Transplantation (FMT) in combination with Nivolumab in subjects with metastatic or inoperable melanoma, microsatellite instability-high (MSI-H) or…
- Conditions
- Melanoma Stage IV, Unresectable Melanoma, NSCLC Stage IV
- Trial name
- NCT04521075
- Testing
- Fecal Microbial Transplantation by capsules
- Where
- Israel
- Volunteers
- 42 people
- Sponsor
- Ella Therapeutics Ltd
Malignant Melanoma
Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
This study was a mixed phase Ib/II, multi-center, open-label study of tebentafusp (IMCgp100) as a single agent, and in combination with durvalumab and/or tremelimumab, in metastatic cutaneous melanoma.
- Trial name
- NCT02535078
- Testing
- Tebentafusp (IMCgp100)
- Where
- 4 sites in United States
- Sponsor
- Immunocore Ltd
NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients, Synovial Sarcoma
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
The target populations for this phase I study with TBI-1301 are patients with advanced solid tumors. Patients' tumors will be required to express NY-ESO-1, which include but is not limited to ovarian cancer, synovial sarcoma…
- Conditions
- NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients, Synovial Sarcoma, Melanoma, Esophageal Cancer
- Trial name
- NCT02869217
- Testing
- Cyclophosphamide, TBI-1301, Fludarabine
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University Health Network, Toronto
Advanced Melanoma
A Clinical Study of T3011 in Subjects With Advanced Melanoma
This clinical study evaluated the tolerability, safety and preliminary efficacy of T3011 in subjects with advanced melanoma.
- Trial name
- NCT06214156
- Testing
- T3011
- Where
- 7 sites in China
- Volunteers
- 42 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd